07
Sep
The weekly term sheet (36)
The first week of September 2025 saw a flurry of dealmaking in life sciences, with over $11.6 billion in
10 min read
Latest
06
Sep
He Who Controls the Term Sheet Controls the Deal
Dear reader,
A brief desk note from your resident author Sebastian. The kettle is still on, the models still overfit,
4 min read
05
Sep
Company of the week: OpenAI
Executive Summary
OpenAI's expansion into healthcare represents a significant inflection point in the artificial intelligence industry, driven by
26 min read
04
Sep
Fund of the week: The Clinique La Prairie Longevity Fund
Fund Launch and Structure
Clinique La Prairie, the Swiss medical spa founded in 1931, launched its Longevity Fund in October
6 min read
03
Sep
AI Models in Biotechnology: 2025 Market Analysis and Performance Assessment
Executive Summary
The integration of artificial intelligence into biotechnology has reached a critical inflection point in 2025. This comprehensive analysis
8 min read
02
Sep
Using Generative AI to Create Synthetic Data in Biotech and Pharma
Executive Summary: The $7.8 billion question
The generative AI revolution in biotech synthetic data generation stands at a critical
13 min read
01
Sep
Yamanaka factors and the reprogramming paradox
The promise of cellular reprogramming through Yamanaka factors represents one of the most profound scientific contradictions in modern medicine: a
8 min read
31
Aug
The weekly term sheet (35)
Weekly Term Sheet: Pharma & Biotech Deals (August 25–28, 2025)
Key Deal Highlights
Deal Type
Companies
Value
Key Asset/
7 min read
30
Aug
Biosimilar Patent Infringement Cases in 2025 Amid a Looming Patent Cliff
Introduction: A Wave of Biosimilar Challenges and the "Patent Cliff"
The biopharmaceutical industry is witnessing a surge of
8 min read
29
Aug
Bristol Myers Squibb's $300 Million Autoimmune Spinout – Investors, Precedents, and Financing Structure
Investor Syndicate and Stakeholders in the $300 Million Round
The new biotech (not yet officially named) is backed by a
9 min read